MicroRNA profiling is associated with platinum-resistance in ovarian cancer
博士 === 國立陽明大學 === 臨床醫學研究所 === 102 === Ovarian cancer is the most lethal cause among gynecological malignancies. Most of them are diagnosed at advanced stage. The standard treatment for advanced ovarian cancer is debulking surgery with adjuvant platinum-paclitaxel combination chemotherapy. In spite o...
Main Authors: | Hua-Hsi Wu, 吳華席 |
---|---|
Other Authors: | Chiou-Chung Yuan |
Format: | Others |
Language: | en_US |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/96496525704321243718 |
Similar Items
-
On the reproducibility of TCGA ovarian cancer microRNA profiles.
by: Ying-Wooi Wan, et al.
Published: (2014-01-01) -
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer
by: Young Eun Choi, et al.
Published: (2016-01-01) -
Integrated extracellular microRNA profiling for ovarian cancer screening
by: Akira Yokoi, et al.
Published: (2018-10-01) -
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
by: Xin Qi, et al.
Published: (2019-10-01) -
MicroRNA characteristics in epithelial ovarian cancer.
by: Kira Philipsen Prahm, et al.
Published: (2021-01-01)